<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36165028</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-7056</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Current opinion in gastroenterology</Title><ISOAbbreviation>Curr Opin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal symptoms in COVID-19: the long and the short of it.</ArticleTitle><Pagination><StartPage>555</StartPage><EndPage>561</EndPage><MedlinePgn>555-561</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MOG.0000000000000876</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">A large and growing number of patients have persistent gastrointestinal symptoms that they attribute to COVID-19. SARS-CoV-2, the virus that causes COVID-19, replicates within the gut and acute COVID-19 is associated with alteration of the gut microbiome. This article reviews recent observational data related to gastrointestinal symptoms in 'long COVID' and discusses pathophysiologic mechanisms that might explain persistent post-COVID gastrointestinal symptoms.</AbstractText><AbstractText Label="RECENT FINDINGS">Gastrointestinal symptoms are present in half of the patients with acute COVID-19, persist 6 months after COVID-19 in 10-25% of patients, and are rated as the most bothersome symptom in 11% of all patients. These symptoms include heartburn, constipation, diarrhoea and abdominal pain and decline in prevalence with the passage of time. Long COVID gastrointestinal symptoms are associated with mental health symptoms (anxiety and depression) that predate COVID-19 and also with mental health symptoms that are concurrent, after recovery from COVID-19. The cause of long COVID gastrointestinal symptoms is unknown and hypotheses include the SARS-CoV-2 virus itself, which infects the gastrointestinal tract; COVID-19, which can be accompanied by gut microbiome changes, a profound systemic inflammatory response and critical illness; and/or effects of pandemic stress on gastrointestinal function and symptom perception, which may be unrelated to either SARS-CoV-2 or to COVID-19.</AbstractText><AbstractText Label="SUMMARY">New, persistent gastrointestinal symptoms are commonly reported after recovery from COVID-19. The pathophysiology of these symptoms is unknown but likely to be multifactorial.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freedberg</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Division of Digestive and Liver Diseases and the Columbia Mailman School of Public Health, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>David Geffen School of Medicine at UCLA, Vatche and Tamar Manoukian Division of Digestive Diseases and the G. Oppenheimer Center for Neurobiology of Stress and Resilience, Los Angeles, CA, US.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 DK123755</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD024899</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Gastroenterol</MedlineTA><NlmUniqueID>8506887</NlmUniqueID><ISSNLinking>0267-1379</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36165028</ArticleId><ArticleId IdType="doi">10.1097/MOG.0000000000000876</ArticleId><ArticleId IdType="pii">00001574-202211000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386:995&#x2013;1007.</Citation></Reference><Reference><Citation>Sultan S, Siddique SM, Altayar O, et al. AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology 2020; 159:1935&#x2013;1948. e5.</Citation></Reference><Reference><Citation>Marasco G, Cremon C, Barbaro MR, et al. Prevalence of gastrointestinal symptoms in severe acute respiratory syndrome coronavirus 2 infection: results of the prospective controlled multinational GI-COVID-19 study. Am J Gastroenterol 2022; 117:147&#x2013;157.</Citation></Reference><Reference><Citation>Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 2020; 159:81&#x2013;95.</Citation></Reference><Reference><Citation>Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal symptoms and coronavirus disease 2019: a case-control study from the United States. Gastroenterology 2020; 159:373&#x2013;375. e2.</Citation></Reference><Reference><Citation>Minodier L, Charrel RN, Ceccaldi PE, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J 2015; 12:215.</Citation></Reference><Reference><Citation>Blackett JW, Li J, Jodorkovsky D, et al. Prevalence and risk factors for gastrointestinal symptoms after recovery from COVID-19. Neurogastroenterol Motil 2021; e14251.</Citation></Reference><Reference><Citation>Blackett JW, Wainberg M, Elkind MSV, et al. Potential long COVID-19 gastrointestinal symptoms 6&#x200a;months after coronavirus infection are associated with mental health symptoms. Gastroenterology 2021; 162:648&#x2013;650.</Citation></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11:16144.</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220&#x2013;232.</Citation></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 2021; 398:747&#x2013;758.</Citation></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Martin-Guerrero J, Navarro-Pardo E, et al. Gastrointestinal symptoms at the acute COVID-19 phase are risk factors for developing gastrointestinal post-COVID symptoms: a multicenter study. Intern Emerg Med 2021; 17:583&#x2013;586.</Citation></Reference><Reference><Citation>Cai M, Bowe B, Xie Y, et al. Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open 2021; 11:e047369.</Citation></Reference><Reference><Citation>Drossman DA, Tack J. Rome Foundation Clinical Diagnostic Criteria for disorders of gut-brain interaction. Gastroenterology 2022; 162:675&#x2013;679.</Citation></Reference><Reference><Citation>Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007; 102:1064&#x2013;1069.</Citation></Reference><Reference><Citation>Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021; 70:698&#x2013;706.</Citation></Reference><Reference><Citation>Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:349&#x2013;357.</Citation></Reference><Reference><Citation>Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47:804&#x2013;811.</Citation></Reference><Reference><Citation>Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98:1578&#x2013;1583.</Citation></Reference><Reference><Citation>Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125:1651&#x2013;1659.</Citation></Reference><Reference><Citation>Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657&#x2013;1664.</Citation></Reference><Reference><Citation>Mawe GM, Hoffman JM. Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013; 10:473&#x2013;486.</Citation></Reference><Reference><Citation>Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology 2021; 160:1486&#x2013;1501.</Citation></Reference><Reference><Citation>Gershon MD. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc 2012; 123:268&#x2013;280. discussion 280.</Citation></Reference><Reference><Citation>Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161:1733&#x2013;1740.</Citation></Reference><Reference><Citation>Olden K, DeGarmo RG, Jhingran P, et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2002; 97:3139&#x2013;3146.</Citation></Reference><Reference><Citation>Emmanuel A, Cools M, Vandeplassche L, et al. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol 2014; 109:887&#x2013;894.</Citation></Reference><Reference><Citation>Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol 2015; 110:741&#x2013;748.</Citation></Reference><Reference><Citation>Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun 2018; 9:3294.</Citation></Reference><Reference><Citation>Reigstad CS, Salmonson CE, Rainey JF 3rd, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 2015; 29:1395&#x2013;1403.</Citation></Reference><Reference><Citation>Yu Y, Villalobos-Hernandez EC, Pradhananga S, et al. Deoxycholic acid activates colonic afferent nerves via 5-HT3 receptor-dependent and -independent mechanisms. Am J Physiol Gastrointest Liver Physiol 2019; 317:G275&#x2013;G284.</Citation></Reference><Reference><Citation>Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158:1831&#x2013;1833. e3.</Citation></Reference><Reference><Citation>Qian Q, Fan L, Liu W, et al. Direct evidence of active SARS-CoV-2 replication in the intestine. Clin Infect Dis 2021; 73:361&#x2013;366.</Citation></Reference><Reference><Citation>Ren Z, Wang H, Cui G, et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut 2021; 70:1253&#x2013;1265.</Citation></Reference><Reference><Citation>Xu X, Zhang W, Guo M, et al. Integrated analysis of gut microbiome and host immune responses in COVID-19. Front Med 2022; 16:263&#x2013;275.</Citation></Reference><Reference><Citation>Mizutani T, Ishizaka A, Koga M, et al. Correlation analysis between gut microbiota alterations and the cytokine response in patients with coronavirus disease during hospitalization. Microbiol Spectr 2022; e0168921.</Citation></Reference><Reference><Citation>Reinold J, Farahpour F, Fehring C, et al. A pro-inflammatory gut microbiome characterizes SARS-CoV-2 infected patients and a reduction in the connectivity of an anti-inflammatory bacterial network associates with severe COVID-19. Front Cell Infect Microbiol 2021; 11:747816.</Citation></Reference><Reference><Citation>Livanos AE, Snider EJ, Whittier S, et al. Rapid gastrointestinal loss of Clostridial clusters IV and XIVa in the ICU associates with an expansion of gut pathogens. PLoS One 2018; 13:e0200322.</Citation></Reference><Reference><Citation>Jeffery IB, O&#x2019;Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61:997&#x2013;1006.</Citation></Reference><Reference><Citation>Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 301:G799&#x2013;G807.</Citation></Reference><Reference><Citation>Carroll IM, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:521&#x2013;530. e248.</Citation></Reference><Reference><Citation>Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017; 152:111&#x2013;123. e8.</Citation></Reference><Reference><Citation>Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020; 159:944&#x2013;955. e8.</Citation></Reference><Reference><Citation>Zhang F, Wan Y, Zuo T, et al. Prolonged impairment of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology 2021; 162:548&#x2013;561.</Citation></Reference><Reference><Citation>Yamada T, Shimizu K, Ogura H, et al. Rapid and sustained long-term decrease of fecal short-chain fatty acids in critically ill patients with systemic inflammatory response syndrome. JPEN J Parenter Enteral Nutr 2015; 39:569&#x2013;577.</Citation></Reference><Reference><Citation>Park SK, Lee CW, Park DI, et al. Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clin Gastroenterol Hepatol 2021; 19:1387&#x2013;1394. e2.</Citation></Reference><Reference><Citation>Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323:1843&#x2013;1844.</Citation></Reference><Reference><Citation>Chertow D, Ramelli S, Grazioli A, et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Pr-print posted online on Dec 20, 2021 on Research Square.</Citation></Reference><Reference><Citation>Britton GJ, Chen-Liaw A, Cossarini F, et al. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Sci Rep 2021; 11:13308.</Citation></Reference><Reference><Citation>Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut 2020; 69:1543&#x2013;1544.</Citation></Reference><Reference><Citation>Shokri-Afra H, Alikhani A, Moradipoodeh B, et al. Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Sci Rep 2021; 11:22001.</Citation></Reference><Reference><Citation>Livanos AE, Jha D, Cossarini F, et al. Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms. Gastroenterology 2021; 160:2435&#x2013;2450. e34.</Citation></Reference><Reference><Citation>Barbara G, Grover M, Bercik P, et al. Rome Foundation Working Team Report on post-infection irritable bowel syndrome. Gastroenterology 2019; 156:46&#x2013;58. e7.</Citation></Reference><Reference><Citation>Pierce M, Hope H, Ford T, et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry 2020; 7:883&#x2013;892.</Citation></Reference><Reference><Citation>Online data from the U.S. Centers for Disease Control and Prevention Household Pulse Survey, accessed March 4, 2022 at https://data.cdc.gov/NCHS/Indicators-of-Anxiety-or-Depression-Based-on-Repor/8pt5-q6wp</Citation></Reference><Reference><Citation>Brulhart M, Klotzbucher V, Lalive R, et al. Mental health concerns during the COVID-19 pandemic as revealed by helpline calls. Nature 2021; 600:121&#x2013;126.</Citation></Reference><Reference><Citation>Collaborators C-MD. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398:1700&#x2013;1712.</Citation></Reference><Reference><Citation>Almario CV, Makaroff K, Alvarez G, et al. Examining the impact of the COVID-19 pandemic on the prevalence of Rome IV Functional Gastrointestinal Disorders. Am J Gastroenterol 2021; 116:S496.</Citation></Reference><Reference><Citation>Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ 2022; 376:e068993.</Citation></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8:416&#x2013;427.</Citation></Reference><Reference><Citation>Kyzar EJ, Purpura LJ, Shah J, et al. Anxiety, depression, insomnia, and trauma-related symptoms following COVID-19 infection at long-term follow-up. Brain Behav Immun Health 2021; 16:100315.</Citation></Reference><Reference><Citation>Parker CH, Naliboff BD, Shih W, et al. Negative events during adulthood are associated with symptom severity and altered stress response in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2019; 17:2245&#x2013;2252.</Citation></Reference><Reference><Citation>Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108&#x2013;2131.</Citation></Reference><Reference><Citation>Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017; 152:1042&#x2013;1054. e1.</Citation></Reference><Reference><Citation>Parker CH, Naliboff BD, Shih W, et al. The role of resilience in irritable bowel syndrome, other chronic gastrointestinal conditions, and the general population. Clin Gastroenterol Hepatol 2021; 19:2541&#x2013;2550. e1.</Citation></Reference><Reference><Citation>Li F, Luo S, Mu W, et al. Effects of sources of social support and resilience on the mental health of different age groups during the COVID-19 pandemic. BMC Psychiatry 2021; 21:16.</Citation></Reference><Reference><Citation>Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62:159&#x2013;176.</Citation></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016; 2:16014.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>